Atorvastatin as a promising anticryptococcal agent

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Cryptococcosis, caused by Cryptococcus gattii, presents a significant global health challenge with high mortality due to limited treatment options and rising drug resistance.
• Drug repositioning offers a viable strategy to identify novel therapeutic approaches for cryptococcosis.
• Atorvastatin (ATO), a cholesterol-lowering drug, is explored as a potential adjuvant therapy.

Purpose of the Study:

• To evaluate Atorvastatin (ATO) as an adjuvant therapy for Cryptococcus gattii infections.
• To investigate the combined efficacy of ATO and fluconazole (FLC) against C. gattii.
• To assess the impact of ATO+FLC on host immune response and fungal characteristics.

Main Methods:

• In vitro assessment of ATO's effects on C. gattii cell membrane ergosterol and capsule properties.
• Evaluation of ATO's impact on macrophage production of reactive oxygen species.
• In vivo study using a murine model of cryptococcosis treated with ATO+FLC.

Main Results:

• ATO+FLC reduced ergosterol content and altered the C. gattii capsule.
• The combination enhanced macrophage reactive oxygen species production.
• ATO+FLC treatment led to increased survival rates, improved clinical status, and reduced fungal load in the lungs and brain of infected mice.

Conclusions:

• Atorvastatin shows potential as an effective adjuvant in combination with fluconazole for treating cryptococcosis.
• The ATO+FLC combination demonstrates significant therapeutic benefits in a preclinical animal model.
• This study provides the first in vivo evidence supporting ATO+FLC as a treatment for cryptococcosis.